SAGARIKA BASU: Open Payments
NPI 1174295687 · RANCHO CUCAMONGA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,568 in 108 payments from 10 companies in 2025. Trend: 2023 $434 · 2024 $1,182 · 2025 $2,568
Food & beverage: $2,407Education: $161
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $701 |
| Madrigal Pharmaceuticals | 19 | $602 |
| Janssen Biotech, Inc. | 12 | $558 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $187 |
| Ardelyx, Inc. | 9 | $185 |
| Phathom Pharmaceuticals, Inc. | 9 | $144 |
| RedHill Biopharma Inc. | 4 | $93 |
| Novo Nordisk Inc | 2 | $55 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Gilead Sciences, Inc. | 1 | $18 |
Products named: REZDIFFRA, TREMFYA, RINVOQ, SKYRIZI, IBSRELA, XIFAXAN, VOQUEZNA, Talicia.
Industry payments across CA — which companies pay providers there.
